STAT3 and T-cell non-Hodgkin lymphoma: Treatment of two NK/T cell lymphoma cell lines that have activating STAT3 mutations with Stattic, a small molecule inhibitor of STAT3 that targets the SH2 domain, resulted in increased apoptosis.